Livongo Health (NASDAQ:LVGO) Posts Earnings Results, Misses Estimates By $0.29 EPS

Share on StockTwits

Livongo Health (NASDAQ:LVGO) issued its quarterly earnings results on Thursday. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.29), Briefing.com reports. The firm had revenue of $40.90 million during the quarter, compared to analyst estimates of $39.74 million. The business’s quarterly revenue was up 155.6% compared to the same quarter last year. Livongo Health updated its FY 2019 guidance to EPS and its Q3 2019 guidance to EPS.

Shares of Livongo Health stock opened at $26.06 on Friday. Livongo Health has a 12-month low of $23.70 and a 12-month high of $45.68.

In other news, Director Hemant Taneja bought 2,678,571 shares of the business’s stock in a transaction that occurred on Monday, July 29th. The shares were purchased at an average cost of $28.00 per share, with a total value of $74,999,988.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Ab (Publ) Kinnevik bought 3,141,795 shares of the business’s stock in a transaction that occurred on Monday, July 29th. The stock was purchased at an average cost of $28.00 per share, for a total transaction of $87,970,260.00. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 5,826,366 shares of company stock worth $162,980,808.

LVGO has been the topic of a number of recent analyst reports. Svb Leerink started coverage on Livongo Health in a research report on Monday, August 19th. They set an “outperform” rating and a $50.00 price target on the stock. Chardan Capital started coverage on Livongo Health in a research report on Friday, August 16th. They set a “neutral” rating and a $40.00 target price on the stock. Canaccord Genuity started coverage on Livongo Health in a research report on Monday, August 19th. They set a “buy” rating and a $46.00 target price on the stock. KeyCorp began coverage on Livongo Health in a research report on Monday, August 19th. They set an “overweight” rating and a $46.00 target price on the stock. Finally, JPMorgan Chase & Co. began coverage on shares of Livongo Health in a report on Monday, August 19th. They set an “overweight” rating and a $43.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. Livongo Health currently has a consensus rating of “Buy” and a consensus price target of $44.20.

About Livongo Health

Livongo Health, Inc provides an integrated suite of solutions for the healthcare industry in North America. It solutions promote health behavior change based on real-time data capture supported by intuitive devices and insights driven by data science. The company offers a platform that provides cellular-connected devices, supplies, informed coaching, data science-enabled insights, and facilitates access to medications.

Featured Story: What is an Initial Public Offering (IPO)?

Receive News & Ratings for Livongo Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Livongo Health and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

IGM Biosciences  Plans to Raise $125 Million in September 18th IPO
IGM Biosciences Plans to Raise $125 Million in September 18th IPO
Hugo Tudor Sells 25,000 Shares of Paragon Banking Group PLC  Stock
Hugo Tudor Sells 25,000 Shares of Paragon Banking Group PLC Stock
Brian Gilvary Purchases 63 Shares of BP plc  Stock
Brian Gilvary Purchases 63 Shares of BP plc Stock
Envista Holdings  Plans to Raise $603 Million in September 18th IPO
Envista Holdings Plans to Raise $603 Million in September 18th IPO
Levi Strauss & Co.’s  Lock-Up Period Set To Expire  on September 17th
Levi Strauss & Co.’s Lock-Up Period Set To Expire on September 17th
Insider Buying: Cobham plc  Insider Buys £150.40 in Stock
Insider Buying: Cobham plc Insider Buys £150.40 in Stock


© 2006-2019 Ticker Report